Login
$SLS
$7.41 -$0.06 (0.84%) After hours

$SLS SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month -

12 Nov 2026 10-Q
10 Nov 2026 SCHEDULE 13G
27 Oct 2026 SCHEDULE 13G/A
11 Aug 2026 8-K: Results of Operations and Financial Condition

–Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event -

11 Aug 2026 10-Q
07 Aug 2026 SCHEDULE 13G
31 Jul 2026 SCHEDULE 13G
27 Jul 2026 8-K: Results of Operations and Financial Condition; Other Events

As of June 30, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $138.3 million. This amount is unaudited and preliminary and is subject to the completion of financ...

25 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

Re: Amended and Restated Severance and Change of Control Letter Agreement

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 16, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) held its Annual Meeting of Stockholders (“Annual Meeting”). There were 115,511,771 shares of common stock, or approximately 62.59% of all outstanding shares, present in p...

18 Jun 2026 Form 4: Stergiou Angelos M., Director

Received 1,065,000 shares as a grant or award

16 Jun 2026 FORM S-8
02 Jun 2026 8-K: Other Events

As previously reported, as of March 31, 2026, SELLAS Life Sciences Group, Inc. (the “Company”) had $107.1 million of cash and cash equivalents.

12 May 2026 8-K: Results of Operations and Financial Condition

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Tri...

12 May 2026 10-Q
24 Apr 2026 SCHEDULE 13G/A
23 Apr 2026 ARS
23 Apr 2026 DEFA14A
23 Apr 2026 Proxy statement: annual meeting on June 16, 2026

CEO pay $1.9M, up 58% · say-on-pay vote

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support